Grocery Pharmacy Conglomerate to Pay $40 Million for Violating False Claims Act

Ahold Delhaize agreed to settle a $40 million lawsuit based on allegations that it reported inflated drug price claims within federal health programs, according to a release from the Western District of Pennsylvania US Attorney’s Office.¹ Within claims to Medicare Part D and other federal entities, the government alleged that Ahold Delhaize’s grocery pharmacies inaccurately reported discounted drug prices.

“Pharmacies in federal health care programs must report truthful prices. Inflating those prices, as alleged here, puts the integrity of taxpayer-funded programs at risk,” Deputy Inspector General for Investigations Scott J. Lampert of the US Department of Health and Human Services Office of Inspector General (HHS-OIG) said in the release. “Working closely with our law enforcement partners, HHS OIG will continue to aggressively pursue such conduct to protect these critical programs and all the people who rely on them.”

The core of the legal action stems from a whistleblower lawsuit filed by Lawrence LaBenne, a pharmacist who worked at an Ahold Delhaize supermarket location in Pennsylvania. Under the qui tam provisions of the False Claims Act, LaBenne acted on behalf of the US to expose discrepancies in how the company reported its “usual and customary” prices.^1-3

For his role in the recovery of public funds, LaBenne is set to receive more than $6 million from the federal share of the settlement, which serves as a stark reminder to pharmacy professionals regarding the high stakes of regulatory compliance.

READ MORE: US Controlled Substance Market Expected to Grow $21 Billion by 2035

The government’s contention centered on the operation of prescription savings programs at stores including Giant, Hannaford, Food Lion, and Stop & Shop. Although these programs offered lower promotional prices to enrolled customers, federal authorities alleged that the pharmacies at these stores failed to report discounted rates as their usual and customary prices when billing Medicare Part D, Medicaid, and TRICARE.^1-3

Because these reported prices serve as a ceiling for government reimbursements, the failure to disclose the lower rates caused taxpayer-funded programs to pay significantly more than required for routine prescriptions.

This settlement comes at a time of immense transition for Ahold Delhaize USA, a Dutch-owned subsidiary that oversees thousands of stores across the eastern US. Despite the company having admitted no wrongdoing, claiming the issues relate to programs discontinued nearly a decade ago, it is navigating a complex financial landscape.^2,3

Recently, the company reported that pharmacy pricing changes tied to the Inflation Reduction Act are expected to reduce its US pharmacy sales by approximately $450 million.²

This federal scrutiny, however, is not unique to Ahold Delhaize, as major competitors like CVS Health and Walgreens Boots Alliance have faced similar False Claims Act litigation regarding pricing disclosures and reimbursement.

For pharmacists on the front lines, these legal challenges highlight the growing tension between operational efficiency and the reimbursement pressure imposed by pharmacy benefit managers (PBMs).⁴

Many retail pharmacies are operating on razor-thin margins, particularly for generic drugs, and also grappling with severe workforce shortages that can compromise service quality. To survive, many grocery pharmacies are evolving into health hubs that integrate clinical services, such as vaccinations and chronic disease management, directly with nutritional counseling and food sales.^4,5

The rise of GLP-1 medications and the integration of artificial intelligence (AI) are further transforming the retail pharmacy model. Pharmacists are increasingly viewed as accessible providers who can bridge the gap between medication therapy and lifestyle choices, helping patients manage complex conditions through personalized nutrition and digital health tools.^4-6

New fintech solutions and platforms like RxSense are also emerging to help grocers better manage reimbursement and improve pricing transparency, potentially preventing the types of backend reporting errors seen in this settlement.⁵

The $40 million settlement reflects a broader market shift where connected systems, rather than individual profit levers, define success. As the US retail pharmacy market approaches an estimated value of $708 billion in 2026, the demand for transparency and integrity in government billing will only intensify.^4,6

Retailers that can successfully align their pricing, loyalty programs, and clinical services into a coherent, customer-centric model will be best-positioned to maintain both fiscal stability and public trust in this highly regulated environment.⁶

“Pharmacies are trusted with charging the contracted prescription prices to Medicare and Medicaid and not unfairly and unlawfully taking advantage of the government and the public,” US Attorney Troy Rivetti for the Western District of Pennsylvania said in the release.¹ “This settlement confirms that the US will take all necessary steps to bring to justice dishonest pharmacies.”

READ MORE: Payer Preference Shifts Toward Unbundled, Transparent PBM Models

REFERENCES

1. Ahold Delhaize USA Inc. to pay $40M for allegedly reporting inflated drug prices on claims to federal healthcare programs. Western District of Pennsylvania US Attorney’s Office. June 10, 2026. Accessed June 24, 2026. https://www.justice.gov/usao-wdpa/pr/ahold-delhaize-usa-inc-pay-40m-allegedly-reporting-inflated-drug-prices-claims-federal

2. Tronco F. Grocery chain pays $40 million fine in pricing scandal deal. The Street. June 20, 2026. Accessed June 24, 2026. https://www.thestreet.com/retail/grocery-chain-ahold-delhaize-fined-price-reporting-inflation

3. Parry H. Ahold Delhaize $40M DOJ settlement: who is eligible for payout. Newsweek. June 18, 2026. Accessed June 24, 2026. https://www.newsweek.com/settlement-ahold-delhaize-hannaford-giant-pharmacy-doj-medicaid-12092392

4. U.S. retail pharmacy market. Market Data Forecast. May 2026. Accessed June 24, 2026. https://www.marketdataforecast.com/market-reports/united-states-retail-pharmacy-market

5. Duff M. The evolution of grocery pharmacy: how GLP-1s and AI are transforming retail health. Progressive Grocer. April 13, 2026. Accessed June 24, 2026. https://progressivegrocer.com/evolution-grocery-pharmacy-how-glp-1s-and-ai-are-transforming-retail-health

6. Aull B, Kilroy T, Marohn E, et al. The state of grocery North America 2026. McKinsey & Company. June 17, 2026. Accessed June 24, 2026. https://www.mckinsey.com/industries/retail/our-insights/the-state-of-grocery-north-america